Gilead’s antiviral is encouraging as coronavirus candidate but isn’t likely to provide long-term shareholder value

Getty Images Shares of Gilead Sciences Inc. rallied in afternoon trading on Monday over investor excitement about a coronavirus treatment candidate. Gilead had said Jan. 31 that it is working with Chinese authorities to test its investigational antiviral remdesivir as a treatment for coronavirus infections. There are currently no […]

Click here to view original web page at www.marketwatch.com